The translation initiation factor eIF4E is elevated in most solid tumors resulting in translation of mRNAs that are normally repressed by their structured 5 0 untranslated region. We have introduced a translational repressor element in a vector ( BK -UTK ) designed to express herpes thymidine kinase ( HTK ). This and a control vector ( BK -TK ) were used to treat experimental tumors of a murine breast cancer line. Both vectors were equally effective in reducing subcutaneous tumors and lung metastases following ganciclovir administration. However, the BK -TK vector was found to be highly toxic, resulting in severe weight loss, degeneration of various organs, and early death of mice following systemic vector delivery, whereas the BK -UTK increased mean survival without toxicity.
O ne of the major determinants of morbidity and mortality for patients with malignant neoplasms is the emergence and progression of metastatic islets resistant to conventional therapy. 1 It has been estimated that at least 50% of patients presenting with a primary tumor already bear metastases at the time of diagnosis. 2 Hence, cancer gene therapy has developed to attack cancers resistant to conventional approaches. Much of the work has been directed at targeting characteristics of the primary tumor, with attention to choice of vector and transcriptional regulation. Two examples of this are the use of tissue -specific promoters and inducible promoters. 3 Despite advances, these approaches still have not been able to address the major problem of how to target metastases without incurring in potential systemic toxicity. Not only are metastases more difficult to reach, but due to their heterogeneity, they frequently do not maintain the specific gene expression pattern of the primary tumor on which the gene therapy was designed. 4, 5 To overcome this problem, the design of an effective cancer gene therapy that permits selective killing of both the primary tumor and distant metastasis must exploit a general characteristic that distinguishes cancer cells from normal cells. Increased expression of the translation initiation factor /proto -oncogene eIF4E has been shown to occur in bladder, 6 breast, 7 cervical, 8 colon, 9 head and neck, 10 and prostate tumors. 11 Therefore, we exploited the ubiquitously increased expression of eIF4E in solid tumors to develop a novel, genetherapy strategy.
eIF4E functions as the cap -binding subunit of the eIF4F complex, an ATP -dependent helicase that unwinds excess secondary structure in the 5 0 untranslated region (UTR ) of mRNAs. The low abundance of eIF4E /F is limiting for the translation of some mRNAs, particularly those with long, G / C -rich 5 0 UTRs. 12 eIF4E overexpression results in a specific increase in the translation of these weakly competitive mRNAs, many of which encode products that stimulate cell growth and angiogenesis, e.g., FGF -2 and VEGF. 13 -15 Hence, we predicted that by placing the complex 5 0 UTR of FGF -2 in front of the herpes simplex virus type 1 thymidine kinase ( HTK ) cDNA, the translation of HTK mRNA could be restricted to cancer cells. Therefore, only cancer cells should express the HTK enzyme and, hence, be susceptible to ganciclovir (GCV ).
We have previously shown (accompanying paper ) that synthesis of the HTK protein from the BK -UTK vector ( containing the 5 0 UTR of FGF -2 ) readily occurs in a panel of murine and human breast carcinoma cell lines, but not in two normal lines. We now show that subcutaneous tumors and experimental lung metastases from the MM2MT murine breast carcinoma line injected in BALB /c mice can be greatly reduced by transfection with the BK -UTK vector followed by GCV administration. Both the BK -UTK and the BK -TK (control ) vectors were nearly equally effective in reducing lung metastasis following systemic delivery. However, The BK -TK /GCV gene therapy was highly toxic to the mice, whereas little to no toxicity was seen in mice treated with the BK -UTK vector.
Methods

Immunohistochemistry of primary tumors
Thin sections ( 5 m ) were dewaxed, slowly rehydrated with progressively wetter alcohol, and finally dipped for 5 minutes in PBS with 0.2% Triton -X100 before application of primary antiserum for 1 hour. The polyclonal antiserum to HTK ( a gift of Dr Bernard Roizman, University of Chicago ) was used at 1:500 dilution. The BioGenex Super Sensitive Detection Kit ( San Ramon, CA ) was used for detection. The slides were counterstained using Mayer's hematoxylin for 5 minutes and briefly rinsed in ammonia water.
Western analysis of cell lysates
From each sample, 20 g of protein were run on 10% SDS -PAGE gels. After SDS /PAGE, the proteins were transferred to an Immobilon -P membrane ( Millipore, Bedford, MA ). The membrane was blocked with 5% milk in TBT ( 0.1% Tween -20 in TBS ) for 1 hour at room temperature and then washed for 10 minutes three times with TBT. Anti-HTK antibody was added at a 1:500 dilution and incubated for 1 hour. Secondary anti -rabbit IgG peroxidase conjugate ( Vector, Burlingame, CA ) was added at a 1:1,000 dilution for 1 hour. The membrane was then washed three times with TBT for 10 minutes and developed using diaminobenzidine ( DAB, BioRad Laboratories, Richmond, CA ). For internal standardization, the membrane was then probed with a monoclonal anti -actin antibody ( Sigma, St. Louis, MO ), to which the level of HTK was normalized, using the same protocol as above with the following changes. Secondary anti -rabbit IgG alkaline phosphatase conjugate ( Vector ) was used, and the blot was developed using BCIP / NBT color development substrate ( Promega, Madison, WI).
Animals
Three-week -old female athymic BALB /c nu /nu and BALB/ c white mice were purchased from Harlan Sprague Dawley (Indianapolis, IN ).
Tumorigenicity assay and tumor ablation
A total of 10 6 MM2MT cells (ATCC, Manassas, VA ) were suspended in 0.1 mL serum and antibiotic -free DMEM medium and injected subcutaneously into the mammary fat pad. Tumor doubling times were determined by measuring daily the smallest ( d) and the largest (D ) diameters with calipers, and the volume was estimated using the formula: V= DÂd 2 Â0.52. The reported numbers are the average of the tumors for each group with standard deviation.
For transfection of primary tumors, 10 g of endotoxinfree purified ( Qiagen, Valencia, CA ) plasmid DNA was diluted in 50 l medium without serum or antibiotics, and in a separate tube, 50 l GenePORTER reagent (Gene Therapy Systems, San Diego, CA ) was mixed with 50 l serum and antibiotic -free medium. The two tubes were then combined at room temperature for 20 minutes, after which the liposome complex was injected between the tumor and the skin of the mouse.
Experimental metastasis
MM2MT cells (10 5 ) were suspended in 150 l of medium and injected in the lateral tail vein of BALB / c white mice. In preliminary experiments, a group of mice was sacrificed every 6 days, and we determined that after 18 days all mice had multiple lung nodules. The lungs were removed, stained with Bouin's solution for contrast, and the lung metastases were counted using a dissecting microscope.
Systemic delivery of vector -liposome
One hundred micrograms of plasmid DNA was diluted in 150 l of medium. In a separate tube, 400 l of GenePORTER reagent was mixed 150 l of medium. After mixing (as above ), the liposome complex was injected in the lateral tail vein. In some experiments, 24 hours later the mice were sacrificed, the various organs harvested, and the vector recovered using Hirt's protocol. 16 Plasmid DNA was then quantified by PCR analysis using primers flanking regions of the BK -Shuttle multiple cloning site 
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GCV administration and toxicity experiments
Two days after injection of the BK -TK or the BK -UTK vector, GCV ( 100 mg /kg in 0.1 mL ) was administered intraperitoneally (i.p. ) once a day, and the treatment was administered for a total of 10 days.
Statistical analysis
The SAS system software ( SAS Institute, Cary, NC ) was used to test the data for normality. Analysis of variance ( ANOVA ) was used to analyze data that were normally distributed. A nonparametric Kaplan -Meier plot, followed by the log -rank test, was used to analyze the overall survival between treatment groups of mice with lung tumors. The Scheffe post hoc test was used to determine the statistical difference between treatment groups in the metastasis and survival experiments following the use of ANOVA. Data was considered statistically significant at the P= .05 level after SAS analysis.
Results
Tumor ablation of MM2MT cells transfected with the BK -TK or BK -UTK vector in BALB / C athymic nude and BALB / C immunocompetent mice
Throughout this work, the BK -Shuttle vector was chosen for several important reasons. First, it is a replicationcompetent, noninfectious episome. Episomal plasmid vectors have two advantages compared to integrating constructs: ( a ) high -level gene expression due to vector amplification and (b ) maintenance of gene expression caused by efficient vertical transfer of the episome during ( tumor ) cell division. This is also in contrast to gene transfer via some other vectors ( particularly retroviral -based ), where the transgene expression falls to very low levels after a few divisions. We also relied on a new liposome, GenePorter, which was reported to have high transfection efficiency in mice.
Initially, we tested whether we could achieve regression of primary tumors from the stably transfected cells after treatment with GCV. Nine mice in each group were injected with MM2MT cells transformed with BK -TK or BK -UTK. Once the tumors reached 50 mm 3 , the mice were treated ip with GCV or PBS for a total of 10 days (Fig 1A ) . This figure shows that, whereas the tumor volumes continued to increase in the PBS groups, there was substantial tumor reduction in both the BK -TK and the BK -UTK groups of mice treated with GCV. To assure that this was not due to nonspecific effects of GCV on tumor growth, 10 mice were injected with untransformed MM2MT cells and again treated with either GCV or PBS (Fig 1B ) . We then tested the effects of in vivo transfection on preformed tumors. MM2MT cells were injected into the mammary fat pad of 18 BALB / c athymic nu/nu mice. When the tumor volumes were approximately 40 mm 3 , the mice were randomly separated into two groups, and either the BK -TK or the BK -UTK vector was delivered by peritumoral injection as a liposomal complex. Two days after vector injection, the BK -TK group (N = 9 ) and the BK -UTK group (N = 9) were each randomly separated into two groups: three mice were assigned for control (PBS ) and six mice were treated daily with 100 mg /kg of GCV ip for a total of 10 days. Figure 2A shows that, whereas the tumor volumes continued to increase in the PBS groups, there was substantial tumor reduction in both the BK -TK and the BK -UTK groups of mice treated with GCV. In fact, one of the six mice in each group had no palpable tumor remaining at the end of the 10-day treatment. In the transfected groups, a significant difference ( P < .01) in the mean tumor volume was found in mice treated with GCV versus PBS.
Because the bystander effect is known to play an instrumental role in the HTK /GCV system, we tested if we could obtain ablation of even larger tumors in immunocompetent mice. MM2MT cells were injected into the mammary fat pad of 18 BALB /c white mice. When the tumor volumes were approximately 100 mm 3 , the mice were randomly assigned to two groups and injected with either the BK -TK or the BK -UTK vectors. When the GCV treatment began, the tumor volumes were approximately 150 mm 3 . Whereas tumor volumes in the control 
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We also attempted to estimate the intratumoral transfection efficiency by immunohistochemistry for expression of the vector-encoded T-Ag. An example is shown in Figure  2C (upper panel ), which shows a large area of immunostain that was only obtained in the sample reacted with T-Ag antiserum, indicating that a significant cross section of tumor was transfected. We confirmed the identity of the T-Ag by a Western blot, showing the expression in an in vivo transfected tumor and comparing it to the expression in the stably transfected cell line MM2MT /BK -TK. Because we assayed equal amounts of protein, the Western blot suggests 
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Comparison of toxicity between the BK -TK and the BK -UTK vectors following systemic delivery
We have previously shown that translation of the UTK mRNA was inhibited in two normal mammary cell lines, but not in cancer lines (accompanying paper ). This resulted in only minimal sensitivity to GCV in the normal cell lines stably transfected with BK -UTK. We wanted to determine if the BK -UTK vector would be less toxic than the BK -TK vector following systemic administration, because the possibility still existed that the UTK mRNA produced from the BK -UTK vector could be translated in some normal tissues with deleterious effects. First, we verified that we could successfully deliver the vectors to various organs, following injection in the lateral tail vein. Three BALB / c white mice were injected in the lateral tail vein with a liposomal complex containing 100 g of the empty BK -Shuttle vector. The vector replicates episomally in transfected cells, so that it can be isolated by a modified Hirt's supernatant protocol from tissue extracts. We monitored the presence of the vector by regular and realtime PCR two days after injection ( Fig 3 ) . Brain, heart, colon, kidney, liver, lung, spleen, and thymus were removed and Hirt's supernatants were prepared. A 143 -bp PCR product specific for the vector ( confirmed by gel electrophoresis ) was detected in all tissues suggesting that the transfection reagent, GenePorter, allows for efficient systemic transfection (Fig 3B ) . Quantitative analysis, relative to standard dilutions of vector, indicated that the amount of episomes in different tissues varied between 0.005 and 1 ng / mg. This also suggests that the vector is amplified ( replicates) in vivo, with the highest accumulation in heart, intestine, and liver.
Next, BALB /c white mice were weighed and injected in the lateral tail vein with a liposomal complex containing either 100 g of the BK -Shuttle ( empty vector, control ), the BK -TK vector, or the BK -UTK vector. Two days later, all mice received one ip injection of GCV for 10 days. Table 1 shows that two of the six mice that received the BK -TK vector were moribund before the end of the experiment (3 and 6 days of GCV treatment). However, no mice expired in either the control group or the BK -UTK group during GCV treatment. In addition, the mean weight of the BK -TK group of mice was decreased by 10% at the end of the experiment, which is in contrast to the 15% gain for the vector control and BK -UTK groups. Besides weight loss, the mice in the BK -TK group showed other signs of morbidity, including lethargy, lack of grooming, and ruffled fur, which were not seen in either the control or the BK -UTK groups. Figure 4 shows one of the most extensive sites of toxicity found in the BK -TK 1 ( 13.8 -17 ) 18.58 ± 2.2 ( 13.44 -21.28 ) 16% Increase 0 3 ( 0 -13 ) 4 Figure 5 Kaplan -Meier analysis of survival of mice following treatment for lung metastases. MM2MT cells ( 10 5 ) were injected into the lateral tail vein of all mice ( N = 50 ). Following treatment, the mice were monitored and the day of death or sacrifice was used for cumulative survival analysis. Circle: control mice, which received only PBS. Red square: mice that received the BK -TK vector and PBS. Green square: mice that received the BK -UTK vector and PBS. Brown square: mice that received the BK -TK vector and GCV. Purple square: mice that received the BK -UTK vector and GCV. MM2MT (U + P)
MM2MT (T + G) MM2MT (U + G)
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Translational control of a suicide gene RJ DeFatta et al mice. Figure 4 , A -C are the intestines of three of the mice from the BK -TK group. Note that these intestines are dark and necrotic, which is in stark contrast to the healthy intestines in panels D -F (BK -Shuttle ) and panels G -I ( BK -UTK ) groups. Other organs in the BK -TK group showed an average loss of mass, which was not seen in the control or BK -UTK group (Table 1) . Overall, the results showed very little difference between the BK -Shuttle and the BK -UTK groups, indicating no gross systemic organ toxicity with BK -UTK / GCV treatment. In contrast, there was substantial reduction in the mean organ weight of the BK -TK. The mean weight percentages of the thymus and the spleen of the BK -TK mice were only 25% of the controls ( P <.01 ) and liver was reduced to 70% (P < .05). It is important to note that the observed toxicity is not due to GCV alone, because no effects were seen in the BK -Shuttle group.
Effect of the BK -TK and the BK -UTK vectors on metastatic tumor burden and survival
Because the BK -UTK vector was shown to have little toxicity when administered systemically, we wanted to determine whether this vector could be an effective therapy for metastasis. Fifty BALB /c white mice were injected in the lateral tail vein with 10 5 MM2MT cells. Eighteen days later, when visible lung nodules were known to appear from previous experiments, 20 mice were injected in the lateral tail vein with 100 g of the BK -TK vector -liposomal complex, and 20 with the BK -UTK vector. After 2 days, GCV was administered ip to 10 mice from both the BK -TK and the BK -UTK groups whereas the other 10 mice from each group, as well as the untransfected group, each received a daily ip injection of PBS. After 10 days of treatment (30 days from the initial injection of the MM2MT cells ), the mice were sacrificed, the lungs removed, and the tumors counted with a dissecting microscope. Mice were sacrificed before the end of the experiment only if they became moribund. The main results of this experiment are summarized in Table 2 . The three groups of mice that received PBS had a mean of 42 -47 lung nodules. In contrast, the group of mice that received either the BK -TK or the BK -UTK vector and GCV had a mean number of lung metastases of 3 (P < .02, compared to the PBS group ). Importantly, two mice in the BK -TK group and four mice in the BK -UTK group had no visible lung metastasis on microscopic inspection ( Table 2 ) . Finally, all groups exhibited an increase in their mean weight, except for the BK -TK group treated with GCV. These mice had a 15% decrease in weight. In addition, the BK -TK group was the only one where any mice had to be sacrificed before the end of the 10 -day treatment with GCV ( 3 of 10 mice ) due to their moribund state. To verify that the results were independent of the BK vector, two additional control groups of 10 mice each were treated with GCV or PBS after systemic injection of empty BK -Sh vector. The mean number of metastases in the GCV and PBS group were 45 (range 17 -70) and 47 (range 14 -77 ), respectively, which was not different from the control group ( untransfected MM2MT +PBS ).
Although there was a substantial reduction in the number of lung nodules in both the BK -TK and the BK -UTK groups following GCV administration, we next wanted to determine if this treatment was capable of increasing longterm survival. To accomplish this, the metastasis experiment was repeated, except that instead of sacrificing the mice after 10 days of treatment ( 30 days from the initial injection of the MM2MT cells ), the experiment was extended to a total of 120 days. Again, the mice were only sacrificed before the end of the experiment if they became moribund. Figure 5 is a Kaplan-Meier graph showing the survival of the various groups of mice, and Table 3 summarizes the results of the experiment.
The mice that were treated with PBS had a mean survival of 42 days whereas the mean length of survival was 58 days for mice treated with the BK -TK vector and GCV, and 96 days for mice treated with the BK -UTK vector and GCV ( Table 3 ). Most importantly, there was a 64% increase in the mean survival of the mice BK -UTK that received GCV compared to the BK -TK mice that received the same treatment. Only the mice in the BK -UTK group treated with GCV had a statistically significant increase in the mean length of survival compared to the MM2MT control group of mice ( P <.01 ). It is also important to note that the BK -TK group of mice that were treated with GCV was the only group in which mice had to be sacrificed before the end of the 10 -day treatment with GCV due to toxicity ( 3 of 10 mice ). When the mice that survived the duration of the experiment were sacrificed, no evidence of lung metastasis was found. All the animals treated with PBS revealed extensive lung metastasis on autopsy.
Discussion
Recent advances in molecular biology have allowed the elucidation of many cellular functions involved in tumorigenesis. These properties are being exploited in novel approaches in which the cancerous cells are targeted in ways Cancer Gene Therapy
Translational control of a suicide gene RJ DeFatta et al that circumvent their resistance to standard therapeutic agents. However, before significant benefits can be seen, some basic advances have to be made. Specifically, the field of cancer gene therapy is currently subject to three major constraints: ( a) method of delivery, (b ) strong specific gene expression, and ( c) efficacy and toxicity. 17 With this in mind, it was our goal to develop a gene therapy system that would circumvent some of these problems. To do this, we generated a vector (BK -UTK ) that would be delivered to all tissues, while limiting HTK synthesis to cancer cells due to their elevated level of eIF4E. This was accomplished by combining elements of translational regulation with a wellestablished gene therapy system (HTK /GCV ). This system is appealing due to its low inherent toxicity 18 and the wellknown bystander effect, where as few as 10% of the cancer cells in a tumor have to express the HTK protein to obtain complete eradication. 19 Instead of developing a viral vector system, we chose an episomally replicating plasmid and the use of liposomal delivery. This is due to the ease of preparation of large amounts of plasmid and cost effectiveness. We found that this system allowed for efficient delivery of the BK -UTK vector to a large number of tissues with little to no adverse effects following GCV treatment. Hence, translational regulation of the HTK gene could potentially be used to treat a variety of cancers. This system prolonged the life span of mice already bearing a large number of metastases with no adverse effects from the treatment. Note also that we employed a single injection of the vector and only 10 days of GCV treatment to assess whether it could eradicate metastases. Perhaps, repeated injections of the vector would ensure greater tissue coverage and hence result in an even more effective cure rate.
